Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02212249

Acronym

Sclerocadh1

Enrollment

Registered

2014-08-08

Start date

2014-05-31

Completion date

2016-03-31

Last updated

2016-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Raynaud Disease, Systemic Sclerosis

Keywords

soluble VE-cadherin, antibody, systemic slerosis

Brief summary

Ve-cadherin is expressed in endothelial cells. Systemic slerosis is a rare auto-immune disease with a endothelial dysfunction. This study is to evaluated the level of soluble VE-cadherin and VE-cadherin antibody in patients with systemic slerosis.

Interventions

BIOLOGICALsoluble Ve cadherin

dosage of soluble VE cadherine in each arms

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* group 1: systemic sclerosis * group 2: raynaud primary disease

Design outcomes

Primary

Measure	Time frame	Description
Level of soluble Ve-cadherin and antibody VE-cadherin with ELISA TEST in Scleroderma group versus Primary Raynaud's Phenomenon	At 30 days average	Level of human sVE and antibody VE-cadherin in blood will be determined by ELISA test in both groups Scleroderma and Primary Raynaud's Phenomenon. The methodology of dosage of sVE is based on the pattern:WO/2008/062314 The methodolody of the dosage of antibody VE-cadherin is based on the pattern WO/2012/136820 . Group Scleroderma (N=60) versus Primary Raynaud's Phenomenon (N=20). Shapiro test.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026